Adlai Nortye (Nasdaq: ANL) is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. Our global infrastructure supports the efficient execution of a robust pipeline of drug candidates. The Company has assembled an experienced management and R&D team, built a differentiated oncology product pipeline, and partnered with numerous leading pharmaceutical companies to accelerate drug discovery and development. We are committed to becoming an innovative R&D enterprise, bringing better treatment options to patients around the world.